Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal
Phase of Trial: Phase IV
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms IMPROVE
- Sponsors AbbVie
- 27 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned initiation date changed from 31 Jul 2017 to 19 Nov 2017.
- 21 Jul 2017 New trial record